Curative Biotechnology, Inc.
Curative Biotechnology, Inc.
Your view on CUBT
Overview
What the company does, where it operates, and who runs it.
About Curative Biotechnology, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- I. Richard Garr
- Headquarters
- 3801 PGA Blvd Suite 600, Palm Beach Gardens, FL, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- I. Richard Garr
- Headquarters
- 3801 PGA Blvd Suite 600, Palm Beach Gardens, FL, US
Curative Biotechnology, Inc. operates as a development-stage biomedical company. The company develops pipeline focusing on therapeutic areas, such as infectious diseases, oncology, and degenerative eye disease.
Its pipeline candidates include IMT504, a novel immune therapy to treat rabies and an adjuvant for vaccines; CUBT906, a fully humanized CD56 monoclonal antibody carrying a pyrrolobenzodiazepine dimer directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor; and Metformin Reformulation for the treatment of degenerative eye disease.
The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine. The company was formerly known as Connectyx Technologies Holdings Group, Inc. and changed its name to Curative Biotechnology, Inc. in November 2020.
Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Boca Raton, Florida.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Curative Biotechnology, Inc., and the rating behind it. CUBT last traded at $0.0073; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Curative Biotechnology, Inc.. Starting points for Curative Biotechnology, Inc.: EPS -$0.25, beta 1.43 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Curative Biotechnology, Inc.. Curative Biotechnology, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Curative Biotechnology, Inc.. Trailing twelve-month EPS for Curative Biotechnology, Inc. stands at -$0.25. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Curative Biotechnology, Inc.. Curative Biotechnology, Inc. has reported as a listed company since 1998. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Curative Biotechnology, Inc. valued side by side against its closest peers. Curative Biotechnology, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Curative Biotechnology, Inc., and how their positions are changing. At a $7.7M market value, institutional positions materially move Curative Biotechnology, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Curative Biotechnology, Inc. executives and directors. Shares of Curative Biotechnology, Inc. have traded between $0.0030 and $0.03 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Curative Biotechnology, Inc.. Curative Biotechnology, Inc. is a $7.7M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Curative Biotechnology, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Curative Biotechnology, Inc.. Coverage tracks Curative Biotechnology, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.